Dublin, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/763qfd/nitric_oxide) has announced the addition of Jain PharmaBiotech's new report "Nitric Oxide - Therapeutics, Markets and Companies" to their offering.
This report Analyses the latest concepts of nitric oxide (NO) and the role it plays in health and disease as a basis for therapeutics and development of new drugs. Major segments of the market for nitric oxide-based drugs are described as well as the companies involved in developing them.
Various pharmacological approaches are described along with their therapeutic relevance. Various approaches are compared using SWOT (Strengths, Weaknesses, Opportunities, Threats) analysis. NO-based therapies are compared with conventional approaches and opportunities for combination with modern biotechnology approaches are described.
Share of drugs where NO is involved in the mechanism of action is analyzed in the worldwide pharmaceutical market for 2014 and is projected to 2019 and 2024 as new drugs with NO-based mechanisms are introduced into the market. Various strategies for developing such drugs are discussed.
Several companies have a product or products involving NO and free radicals. The report includes profiles of 34 companies involved in this area of which 8 have a significant interest in NO-based therapeutics. Other players are pharmaceutical and biotechnology companies as well as suppliers of products for NO research. Unfulfilled needs in the development of NO-based therapeutics are identified. Important 15 collaborations in this area are tabulated.
There are numerous publications relevant to NO. Selected 500 references are included in the bibliography. The text is supplemented with 25 tables and 26 figures.It is concluded that the future prospects for NO-based therapies are bright and fit in with biotechnology-based approaches to modern drug discovery and development. It is anticipated that some of these products will help in meeting the unfulfilled needs in human therapeutics.
Key Topics Covered:
Executive Summary
1. Introduction
2. Nitric Oxide Pathways
3. Role of NO in Physiology
4. Role of NO in Diseases
5. Pharmacology of Nitric Oxide
6. Therapeutic Applications
7. Evaluation of NO-Based Drugs
8. Markets for NO-based Therapies
9. Companies
10. References
For more information visit http://www.researchandmarkets.com/research/763qfd/nitric_oxide
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Healthcare and Medical Devices


Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Muji Owner Ryohin Keikaku Stock Soars After Raising Full-Year Earnings Forecast
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 



